After reaching their peaks in late November, both the BioWorld Drug Developers Index and the Nasdaq Biotechnology Index finished the year slightly down from those highs.

Total med-tech financing activity surged in the fourth quarter of 2025, with $16.21 billion raised across all financing categories, more than double the $5.78 billion recorded in Q3 and the strongest ...

Automata Technologies Ltd. raised $45 million in a series C funding round that included a strategic investment partnership with Danaher Corp. The funds will be used to support the scaling of customer ...

University of Florida researchers have synthesized proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1)- ...

The EMA has started a review of Amgen Inc.’s Tavneos (avacopan) after questions were raised about the integrity of the data in the Advocate study that the agency assessed when granting approval of the ...

Astrazeneca plc has signed a new strategic collaboration agreement with CSPC Pharmaceutical Group Ltd. to advance the development of next-generation therapies for obesity and type 2 diabetes across ...

Elevar Therapeutics Inc. appointed Kim Dong-gun (DG) as CEO Jan. 29, as the company focuses on post-NDA strategies for lirafugratinib in bile duct cancer, and the twice-rejected ...

Ahead Therapeutics SL has been awarded an Industry Discovery and Development Partnership (IDDP) grant from Breakthrough T1D to support progression of the company’s proprietary Mimi-Top (mimicking ...

Bone metastasis represents a challenge in cancer therapy because of the independency of immunosuppression, neuropathic pain and osteolytic destruction. Recent evidence has suggested the tumor ...

DFNB16, a recessive form of mild-to-moderate human deafness, is caused by mutations in the STRC gene, which encodes stereocilin, a protein essential for the effective function of outer hair cells as ...

Terns Pharmaceuticals Inc. has reported triazole compounds acting as gastric inhibitory polypeptide receptor (GIPR) antagonists. They are intended for use in the treatment of diabetes, obesity, liver ...

To address the dual bottlenecks of immunosuppressive cell infiltration and impaired T-cell function in the tumor microenvironment (TME), researchers from the School of Pharmaceutical Sciences of Sun ...